ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1771

Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics

Mireia Lopez Corbeto1, yolanda Guillen2, Irene Bonafonte3, Nuria Palau4, Raül Tortosa4, Estefanía Moreno Ruzafa1, Antonio Julia5 and Sara Marsal6, 1Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, 2Imidomics, Inc, Barcelona, Spain, 3Berufserfahrung: Helmholtz Munich, Barcelona, Spain, 4Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, 5Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 6Vall Hebron Hospital Research Institute, Barcelona, Spain

Meeting: ACR Convergence 2024

Keywords: Genomics and Proteomics, Juvenile Inflammatory Arthritis, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Basic Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of cases, often presenting with asymmetrical arthritis and a high risk for uveitis (oJIA-U). The specific immune cells causing synovial inflammation and uveitis remain unclear. While studies on T cells in oJIA have focused on CD4+ T cells, the role of other immune subsets like CD8+ T cells and innate immune cells is increasingly recognized.

Methods: To identify pathogenic immune cells in oJIA, we performed single-cell RNA sequencing (scRNA-Seq, 10x Genomics) and TCR sequencing on 132,824 peripheral blood (PB) and synovial fluid (SF) mononuclear cells (MCs) from three newly diagnosed oJIA patients. We also analyzed PBMCs from four oJIA-U patients and four healthy controls (HCs). Analysis of scRNA-Seq data included differential abundance of cell subtypes, differential gene expression as well as characterization of the and the clonal architecture of alpha-/beta-paired T-cell receptor strands in SF and PB. Additionally, we characterized the plasma proteomic profile from newly diagnosed oJIA, oJIA-U, HCs with a panel 235 proteins related with inflammation (Olink).

Results: Intermediate monocytes, regulatory T cells, activated CD8+ T cells, and NKG2C+ effector memory CD8+ T cells were found in the SF of oJIA patients. These cell populations were also found to be significantly reduced in the PB of oJIA patients, indicating active recruitment to inflamed synovium (P< 0.05). Significant transcriptional differences in activated effector memory CD8+ T cells and NKG2C+ effector memory CD8+ T cells from SF and PB of oJIA patients compared to HCs showed overexpression of key proinflammatory genes like CCL5, GMZA, GZMK and CXCL13 (FDR< 0.05). In oJIA-U patients, circulating dendritic cells types 1 and 4, and mature NK cells were more prevalent compared to oJIA patients without uveitis as well as HCs. These cells in PB from oJIA-U patients had up-regulation of type I and III interferon signaling and MHC class I antigen processing, with CD56+ dim mature NKs overexpressing PRF1, FECR1G, CCL4 (MIP-1β), and B2M. Plasma protein analysis showed increased levels of innate immune proteins like FGF-23, TRAIL, C2, IL-18R1, and IL-6 in oJIA patients compared to HCs (P< 0.05). Severe oJIA-U patients had elevated GZH and MMP-1 plasmatic levels, consistent with innate immune cell involvement.

Conclusion: This study provides the first combined single-cell atlas of oJIA and oJIA-U, providing insights into cellular dynamics and potential cellular drivers of both pediatric rheumatologic diseases. Investigating these populations may improve understanding of underlying mechanisms and help to develop more specific therapeutic strategies.


Disclosures: M. Lopez Corbeto: None; y. Guillen: None; I. Bonafonte: None; N. Palau: None; R. Tortosa: None; E. Moreno Ruzafa: None; A. Julia: None; S. Marsal: None.

To cite this abstract in AMA style:

Lopez Corbeto M, Guillen y, Bonafonte I, Palau N, Tortosa R, Moreno Ruzafa E, Julia A, Marsal S. Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/characterization-of-pathogenic-immune-mechanisms-in-oligoarticular-juvenile-idiopathic-arthritis-applying-single-cell-transcriptomics-and-proteomics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-pathogenic-immune-mechanisms-in-oligoarticular-juvenile-idiopathic-arthritis-applying-single-cell-transcriptomics-and-proteomics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology